1st Counsel – Lifestyle
Author:
SAB Biotherapeutics, Inc.
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
April 22, 2026
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
April 15, 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
March 19, 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
March 10, 2026
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
March 9, 2026